BCDA · BioCardia, Inc.
$0.97
+0.04 (+4.82%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within their control and cannot be assessed as being probable of occurring.”View the 10-Q filed Aug 12, 2026
Market Cap
$14.74M
Shares
15.14M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$8.23M
-3.5%
FY2025
Gross Margin
100%
FY2011
Operating Margin
-13794.83%
-11353.7pp
FY2024
Operating Cash Flow
-$7.44M
+5.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $58K | $477K | $1.35M | $1.02M | $145K | $710K | $625K | $479K | $576K | $904K | — | — | — | $12K | $0 | |
| — | — | — | — | — | $0 | $4000 | $358K | $517K | $690K | $746K | $1.06M | — | — | $0 | $0 | $0 | |
| $141K | — | — | — | — | — | — | — | — | — | — | — | — | — | $62K | $12K | $0 | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 100% | — | |
| $4.19M | $4.96M | $4.39M | $7.73M | $8.83M | $8.56M | $9.81M | $8.56M | $8.45M | $5.8M | $3.33M | $1.52M | — | — | — | — | — | |
| $561K | — | — | — | — | — | — | — | — | — | — | $198K | $196K | $259K | $401K | $630K | $583K | |
| $3.2M | $3.32M | $3.67M | $4.4M | $4.42M | $5.09M | $5.86M | $6M | $5.76M | $6.4M | $4.11M | $3.73M | — | — | — | — | — | |
| — | $24K | $67K | $84K | $82K | $60K | $68K | $111K | $88K | $78K | $39K | $47K | — | — | — | $0 | $967K | |
| $7.39M | $8.28M | $8.06M | $12.12M | $13.25M | $13.65M | $15.67M | $14.92M | $14.73M | $12.88M | $8.18M | $6.31M | — | — | — | — | — | |
| -$7.39M | -$8.28M | -$8M | -$11.64M | -$11.9M | -$12.63M | -$15.53M | -$14.21M | -$14.1M | -$12.41M | -$7.61M | -$5.41M | $231K | $9000 | -$339K | -$618K | -$583K | |
| — | — | -13794.83% | -2441.09% | -880.25% | -1244.33% | -10709.66% | -2001.83% | -2256.32% | -2589.77% | -1320.83% | -598.34% | — | — | — | -5150% | — | |
| — | -$8.25M | -$7.93M | -$11.56M | -$11.82M | -$12.57M | -$15.46M | -$14.1M | -$14.01M | -$12.33M | -$7.57M | -$5.36M | — | — | — | -$618K | $384K | |
| — | — | — | — | — | $0 | $3000 | $112K | — | $0 | $1.74M | $1.39M | — | — | — | — | — | |
| — | — | — | — | — | $9000 | $21K | — | — | — | — | — | — | — | — | — | — | |
| $51K | $50K | $55K | $73K | -$6000 | $7000 | $525K | -$496K | $115K | $97K | -$2.7M | -$1.29M | — | — | — | — | — | |
| $5.37M | — | — | — | — | — | — | — | — | — | — | $322K | $234K | $19K | -$331K | — | — | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | |
| -$7.34M | -$8.23M | -$7.95M | -$11.57M | -$11.91M | -$12.62M | -$15M | -$14.71M | -$13.99M | -$12.31M | -$10.31M | -$6.7M | $234K | $19K | $305K | $9.66M | -$11.51M | |
| — | — | -13700% | -2425.79% | -880.7% | -1243.65% | -10347.59% | -2071.69% | -2237.92% | -2569.52% | -1789.93% | -740.82% | — | — | — | 80516.67% | — | |
| USD/shares | — | -$1.23 | -$2.90 | -$8.19 | -$10.05 | -$11.25 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 6.67M | 2.74M | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 557.89K | 104.02K | — | — | — | — | — |
| shares | — | — | — | — | — | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 557.89K | 15.35M | 15.35M | 15.35M | 15.35M | 15.35M | 15.35M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.24×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.97×
Peer medians compare against the 222 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Collaboration Agreement | $477,000 | $1,349,000 | $1,014,000 | $132,000 |
| Product | $0 | $3,000 | $1,000 | $13,000 |